Now Is The Time To Build A Position In Candel Therapeutics Inc (NASDAQ:CADL)

In the last trading session, 1.03 million Candel Therapeutics Inc (NASDAQ:CADL) shares changed hands as the company’s beta touched -0.91. With the company’s per share price at $5.06 changed hands at $0.16 or 3.27% during last session, the market valuation stood at $269.82M. CADL’s last price was a discount, traded about -188.54% off its 52-week high of $14.60. The share price had its 52-week low at $3.79, which suggests the last value was 25.1% up since then. When we look at Candel Therapeutics Inc’s average trading volume, we note the 10-day average is 1.05 million shares, with the 3-month average coming to 975.27K.

Analysts gave the Candel Therapeutics Inc (CADL) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 1 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended CADL as a Hold, 1 felt it is a Buy and 0 rated the stock as Underweight. Candel Therapeutics Inc’s EPS for the current quarter is expected to be -0.17.

Candel Therapeutics Inc (NASDAQ:CADL) trade information

Instantly CADL was in green as seen at the end of in last trading. With action 8.35%, the performance over the past five days has been green. The company’s shares are showing year-to-date downside of -11.38%, with the 5-day performance at 8.35% in the green. However, in the 30-day time frame, Candel Therapeutics Inc (NASDAQ:CADL) is -13.50% down. Looking at the short shares, we see there were 6.26 million shares sold at short interest cover period of 6.49 days.

Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -43.86%. The 2025 estimates are for Candel Therapeutics Inc earnings to increase by 53.39%, but the outlook for the next 5-year period is at 33.18% per year.

CADL Dividends

Candel Therapeutics Inc is expected to release its next quarterly earnings report on 2025-May-13.

Candel Therapeutics Inc (NASDAQ:CADL)’s Major holders

If we look at who the major shareholders are, we find that insiders hold 17.53% of Candel Therapeutics Inc shares while 40.72% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 49.38%. There are 40.72% institutions holding the Candel Therapeutics Inc stock share, with NORTHPOND VENTURES, LLC the top institutional holder. As of 2024-06-30, the company held 6.477% of the shares, roughly 1.94 million CADL shares worth $12.0 million.

BLACKROCK INC. holds the second largest percentage of outstanding shares, with 2.7548% or 0.82 million shares worth $5.1 million as of 2024-06-30.

Among Mutual Funds, the top two as of Apr 30, 2025 were Fidelity Select Portfolios-Biotechnology Portfolio and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund . With 5.54 shares estimated at $28.06 million under it, the former controlled 11.07% of total outstanding shares. On the other hand, VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund held about 1.73% of the shares, roughly 866.65 shares worth around $4.39 million.

Marketing Sentinel
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.